Tomasetti et al . were combining clinical and experimental observations with mathematical formulas to estimate that in advanced GIST, the genetic changes responsible for resistance are already present from the beginning of treatment. The model is of highest interest, especially in respect of second and third line treatment with targeted therapies. However, prospective validation is required before this model can be incorporated in combination drug trials.